Scott Rottinghaus
Chief Tech/Sci/R&D Officer at ENANTA PHARMACEUTICALS, INC.
Net worth: 493 891 $ as of 2024-03-30
Profile
Scott T.
Rottinghaus is currently the Chief Medical Officer & Senior Vice President at Enanta Pharmaceuticals, Inc. Previously, he worked as the Vice President & Head-Clinical Development at Alexion Pharmaceuticals, Inc. He received his doctorate from Mayo Medical School, his graduate degree from the University of Cambridge, and his undergraduate degree from Kansas State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-11 | 28,287 ( 0.13% ) | 493 891 $ | 2024-03-30 |
Scott Rottinghaus active positions
| Companies | Position | Start |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2022-08-07 |
Former positions of Scott Rottinghaus
| Companies | Position | End |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Scott Rottinghaus
| University of Cambridge | Graduate Degree |
| Kansas State University | Undergraduate Degree |
| Mayo Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Scott Rottinghaus
